Priyanka Grover
Stock Analyst at J.P. Morgan
(0.17)
# 4,654
Out of 5,043 analysts
27
Total ratings
13.6%
Success rate
-24.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Priyanka Grover
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Initiated Coverage: Buy | $60 | $26.40 | +127.27% | 1 | Oct 8, 2026 | |
| ELVN Enliven Therapeutics | Initiated Coverage: Buy | $75 | $40.98 | +83.02% | 1 | Oct 1, 2026 | |
| KURA Kura Oncology | Initiated Coverage: Buy | $30 | $10.60 | +183.02% | 1 | Oct 1, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterated: Buy | n/a | $3.31 | - | 4 | Sep 15, 2026 | |
| MREO Mereo BioPharma Group | Reiterated: Sell | n/a | $0.3499 | - | 9 | Sep 15, 2026 | |
| NUVB Nuvation Bio | Reiterated: Buy | n/a | $5.00 | - | 2 | Sep 15, 2026 | |
| RXRX Recursion Pharmaceuticals | Reiterated: Buy | n/a | $4.36 | - | 3 | Sep 15, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | n/a | $90.78 | - | 3 | Sep 15, 2026 | |
| RLAY Relay Therapeutics | Reiterated: Buy | $31 | $17.88 | +73.38% | 3 | Aug 14, 2026 |
Neurogene
Oct 8, 2026
Initiated Coverage: Buy
Price Target: $60
Current: $26.40
Upside: +127.27%
Enliven Therapeutics
Oct 1, 2026
Initiated Coverage: Buy
Price Target: $75
Current: $40.98
Upside: +83.02%
Kura Oncology
Oct 1, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $10.60
Upside: +183.02%
BridgeBio Oncology Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.31
Upside: -
Mereo BioPharma Group
Sep 15, 2026
Reiterated: Sell
Price Target: n/a
Current: $0.3499
Upside: -
Nuvation Bio
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.00
Upside: -
Recursion Pharmaceuticals
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.36
Upside: -
Rhythm Pharmaceuticals
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $90.78
Upside: -
Relay Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $31
Current: $17.88
Upside: +73.38%